Q2 EPS Estimate for Keros Therapeutics Reduced by Analyst
Keros Therapeutics, Inc. (NASDAQ:KROS – Free Report) – Research analysts at William Blair dropped their Q2 2025 EPS estimates for shares of Keros Therapeutics in a research report issued on Tuesday, May 6th. William Blair analyst M. Phipps now expects that the company will post earnings per share of ($1.08) for the quarter, down from […]
Keros Therapeutics, Inc. (NASDAQ:KROS – Free Report) – Research analysts at William Blair dropped their Q2 2025 EPS estimates for shares of Keros Therapeutics in a research report issued on Tuesday, May 6th. William Blair analyst M. Phipps now expects that the company will post earnings per share of ($1.08) for the quarter, down from […]
